Myocarditis Update - Israeli Data - Sweden - Denmark - So much more
What this video covers
Recorded in early October 2021 — as the myocarditis safety signal was still emerging — Dr. Vinay Prasad rounds up the international data on post-vaccination heart inflammation. The centerpiece is Israeli Ministry of Health data reporting myocarditis rates as frequent as roughly 1 in 3,000 to 1 in 6,000 among young men after the second mRNA dose, numbers Prasad presents as far higher than the “rare” framing used by U.S. officials.
He then turns to Scandinavia: in October 2021, Sweden and Denmark restricted or paused the use of Moderna’s vaccine in younger age groups over myocarditis concerns — decisions Prasad holds up as examples of regulators responding proportionally to subgroup-specific risk. The contrast he draws is with the United States, where recommendations remained uniform across age, sex, and product despite the same data being available.
The video is an early installment of what became Prasad’s signature campaign: risk-stratified vaccine policy. His argument is that regulators who could see the myocarditis signal concentrating in young males had an obligation to differentiate recommendations — by age, sex, product, and dosing interval — rather than pressing ahead with one-size-fits-all guidance.
Two specifics in the video deserve capture. First, Prasad says an early preprint on myocarditis incidence in 12–15-year-old boys — roughly 1 in 6,800, based on a VAERS analysis reviewed by an expert cardiologist — was, in his view, unfairly attacked for using VAERS and then vindicated by the NEJM Israeli data putting the range around 1 in 6,000–10,000. He calls the attacks on those authors anti-science. Second, he pushes back on “mild” reassurances: he notes that at least one affected boy got very sick, that some showed cardiac MRI changes, and that the long-term significance of those changes was an open and important question — “most cases are mild” is not the same as “all cases are guaranteed to be mild.” He also cites his Newsweek piece opposing Los Angeles’s two-dose school mandate, arguing mandates should never be imposed where there is no global scientific consensus, and this was a live dispute.
Key points
- Prasad presents Israeli Ministry of Health figures reporting post-second-dose myocarditis as frequent as roughly 1 in 3,000–6,000 in young men — rates he argues belied official “rare event” reassurances.
- He covers Sweden’s and Denmark’s October 2021 decisions to restrict Moderna use in younger people over myocarditis signals, presenting them as proportionate, data-driven responses.
- According to Prasad, the same subgroup data was available to U.S. regulators, who nevertheless maintained uniform recommendations — a failure of risk stratification.
- He argues that vaccine policy should have differentiated by age, sex, product, and dosing interval, rather than treating a 16-year-old boy and a 75-year-old woman identically.
- Prasad contends the reluctance to stratify reflected institutional inertia and an unwillingness to complicate the pro-vaccination message, not the science.
- He flags the dosing interval as a modifiable risk factor — longer intervals between doses were already associated with lower myocarditis rates in international data.
- Prasad says an early preprint estimating roughly 1 in 6,800 myocarditis in 12–15-year-old boys was unfairly attacked for its VAERS-based analysis and then vindicated by the NEJM Israeli data (roughly 1 in 6,000–10,000).
- He pushes back on “mild” reassurances, noting some affected boys showed cardiac MRI changes of unknown long-term significance — “most cases are mild” is not the same as all being guaranteed mild.
- He cites his Newsweek piece opposing Los Angeles’s two-dose school mandate, arguing mandates should not be imposed where the science is a live dispute.
- Context: U.S. officials maintained that the benefits of vaccination outweighed the myocarditis risk even in young men, characterizing most cases as mild and resolving; Prasad’s position was that the risk-benefit math did not hold for the lowest-risk subgroups.